Previous studies have shown that ALK+ NSCLC harbored a significantly lower CD8+ T cell infiltration than KRAS- or non-ALK/EGFR-mutated NSCLC [4,5], or a lower proportion of CD8+ T cells than EGFR-mutated NSCLC [9]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.